Meyer Handelman Co. trimmed its position in Avanos Medical Inc (NYSE:AVNS) by 8.8% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 15,635 shares of the company’s stock after selling 1,500 shares during the quarter. Meyer Handelman Co.’s holdings in Avanos Medical were worth $701,000 as of its most recent SEC filing.
A number of other large investors have also recently bought and sold shares of the business. First Hawaiian Bank acquired a new position in shares of Avanos Medical in the 4th quarter worth approximately $45,000. Bollard Group LLC acquired a new position in shares of Avanos Medical in the 3rd quarter worth approximately $100,000. Rehmann Capital Advisory Group acquired a new position in shares of Avanos Medical in the 3rd quarter worth approximately $108,000. Whittier Trust Co. acquired a new position in shares of Avanos Medical in the 3rd quarter worth approximately $110,000. Finally, Public Employees Retirement System of Ohio acquired a new position in shares of Avanos Medical in the 2nd quarter worth approximately $136,000. Institutional investors own 91.07% of the company’s stock.
In other news, CEO Joseph Fralin Woody acquired 3,500 shares of the company’s stock in a transaction on Wednesday, November 28th. The shares were bought at an average cost of $43.35 per share, with a total value of $151,725.00. The purchase was disclosed in a filing with the SEC, which is available at this hyperlink. Also, CFO Steven E. Voskuil acquired 2,000 shares of the company’s stock in a transaction on Tuesday, November 27th. The stock was purchased at an average cost of $43.74 per share, for a total transaction of $87,480.00. The disclosure for this purchase can be found here. Over the last quarter, insiders have acquired 6,500 shares of company stock worth $286,685. 1.44% of the stock is owned by company insiders.
A number of research firms have issued reports on AVNS. Barclays began coverage on shares of Avanos Medical in a report on Monday, October 15th. They set an “equal weight” rating and a $69.00 target price on the stock. Zacks Investment Research lowered shares of Avanos Medical from a “hold” rating to a “sell” rating in a report on Wednesday, November 7th. TheStreet lowered shares of Avanos Medical from a “b-” rating to a “c” rating in a report on Wednesday, November 7th. Finally, KeyCorp reduced their target price on shares of Avanos Medical from $68.00 to $67.00 and set an “overweight” rating on the stock in a report on Tuesday, December 18th. Two investment analysts have rated the stock with a sell rating, one has given a hold rating and two have issued a buy rating to the stock. The stock has an average rating of “Hold” and a consensus target price of $67.25.
About Avanos Medical
Avanos Medical, Inc operates as a medical technology company that focuses on eliminating pain, speeding recovery, and preventing infection for healthcare providers and patients worldwide. Its Medical Devices segment provides a portfolio of products that focuses on respiratory and digestive health, along with surgical and interventional pain management.
Featured Article: Are all No-Load Funds Equal?
Receive News & Ratings for Avanos Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avanos Medical and related companies with MarketBeat.com's FREE daily email newsletter.